vimarsana.com

Page 26 - காப்புரிமை பெற்றது மருந்துகள் ஒழுங்குமுறைகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Podcast Trial Alert: VLSI Technologies v Intel II — Jury Trial Day 2 - Litigation, Mediation & Arbitration

Day 2 s Order of Play was: Plaintiff s case-in-chief Dr. Murali Annavaram, Testing Expert Deposition designations for several Intel witnesses It became clear that as to both asserted patents, VLSI s infringement allegations centered on the FIVR, or fully integrated voltage regulator, feature of the accused chips. According to VLSI, Intel added the FIVR feature to the chips in 2013, which was highly valued by Intel customers. Dr. Annavaram testified that, according to tests he did using Intel benchmark tools, the accused FIVR feature greatly increased the performance of the accused chips. Today, VLSI s damages expert Dr. Sullivan will testify.  To learn more about Day 2, please listen to DaWanna McCray s

Life Sciences 2021 Guide - Food, Drugs, Healthcare, Life Sciences

1 . LIFE SCIENCES REGULATORY FRAMEWORK 1.1 Legislation and Regulation for Pharmaceuticals and Medical Devices The primary legislation governing the authorisation, marketing, sale and supply of pharmaceutical products by the US Food and Drug Administration (FDA) is the Federal Food, Drug, and Cosmetic Act (FD&C Act), which has been amended many times over the years to reflect increasing FDA mandates for the regulation of pharmaceutical products. The Public Health Service Act (PHS Act) is the specific authority utilised to approve or license biologic (including biosimilar) products. The primary FDA regulations governing drugs and biologics are found at Chapter 21 of the Code of Federal Regulations. Controlled substances, such as opioids, are

The Right to Freedom of Speech, Expression and Peaceful Assembly of CAA Protesters Recognised by Madurai Bench of Madras High Court

Please Wait .. The Right to Freedom of Speech, Expression and Peaceful Assembly of CAA Protesters Recognised by Madurai Bench of Madras High Court Please Wait .. The Madurai Bench of the Madras High Court quashed an FIR lodged against peaceful protesters. The grounds for such rejection were the fact that the protest was peaceful and nothing untoward had occurred during the protests. Several countries of the world recognise the right of peaceful assembly. Peaceful protests are an essential part in the backdrop of democracy. OVERVIEW In an order dated 25th of March, 2021, the Madurai Bench of the Madras High Court quashed an FIR against protesters of Citizenship Amendment Act (Bill) on the streets, which in the opinion of the police created not only public nuisance, but also hindered the smooth flow of traffic in the city.

Disclosing AI Inventions - Part I: Identifying The Unique Disclosure Issues - Technology

To print this article, all you need is to be registered or login on Mondaq.com. Our recent post Tracking AI Prosecution Trends at the U.S. Patent Office presented USPTO data which suggests that future prosecution of AI inventions may be less focused on patent eligibility under 35 U.S.C. §101 and more focused on the traditional requirements of §§ 102, 103 and 112. This post is the first of a two part series looking into the challenges that AI inventions present to one of these traditional requirements: patent disclosure under 35 U.S.C. §112(a). In this Part I, we identify the unique disclosure issues with AI inventions. In Part II, we provide

Patent Owner Tip #1 For Surviving An Instituted IPR: Approach IPR Depositions Like A Cross-Examination - Intellectual Property

As a Patent Owner in an instituted Inter Partes Reviews ( IPR ), one of the first and most critical tasks before you is deposing the Petitioner s witnesses, including its experts.  But approaching an IPR deposition like a typical litigation deposition could be a big mistake.  Unlike a typical litigation deposition, where one thoroughly probes a witness on all relevant issues to gain a better understanding of what the deponent knows, an IPR deposition needs to be treated more like a cross-examination at trial.  This is because the IPR witness has already provided his or her testimony in the IPR through a declaration and, under normal

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.